135782-11-5Relevant articles and documents
ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR
-
Paragraph 0536-0539, (2017/06/12)
The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.
AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE
-
, (2013/06/05)
The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
A Synthesis of 1-Azabicycloheptane-3-carboxylic Acid Esters in Enantiomerically Pure Form
Cottrell, Ian F.,Hands, David,Kennedy, Derek J.,Paul, Kerensa J.,Wright, Stanley H. B.,Hoogsteen, Karst
, p. 1091 - 1097 (2007/10/02)
A novel synthesis of ethyl 1-azabicycloheptane-3-carboxylate via 1-benzylperhydropyranopyrrol-4-one and 1-benzyl-3-(2-bromoethyl)-4-ethoxycarbonylpyrrolidinium bromide is described.Modification of the method, by incorporation of a chiral substituted benzyl group on the nitrogen atom, has led to the first reported process for the preparation of these esters in enantiomerically pure form.The absolute configuration of the bicyclic esters was deduced by X-ray crystallography of an intermediate, 2-perhydropyranopyrrole-4-one.